Connect with us

Hi, what are you looking for?

Jewish Business News

IPOs

Liver Disease Biotech Galmed Files For A $35 Million IPO


Galmed Pharmaceuticals Ltd., a clinical-stage biotech developing therapies for liver diseases and gallstones, filed on Thursday with the SEC to raise up to $35 million in an initial public offering,  at a company value of $100 million, before money.

Galmed is due to begin a Phase IIb clinical trial of Aramchol for the treatment of non-alcoholic steatohepatitis (NASH), or fatty liver disease, for patients with both fatty livers and insulin resistance.

Haim Horowitz and  Allen Baharaff

Chaim Hurvitz and  Allen Baharaff  / Eyal Itzhar,  Globes

Galmed is owned by CEO Allen Baharaff, with a 53% stake; Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) director Chaim Hurvitz (10%); David and Dvora Goldfarb (6.7%), and Migdal Insurance and Financial Holdings Ltd. (TASE: MGDL) (4.4%). The company has raised less than $10 million to date.

The company plans to begin the Phase IIb clinical trial on 240 patients in the second half of 2014, with the interim results due in 2015, and the final results due by the end 2016. The company has no profits, and lost $17.4 million in 2013. It has $137, 000 in cash.

The Tel Aviv, Israel-based company, which was founded in 2000, plans to list on the NASDAQ under the symbol GLMD.

Galmed Pharmaceuticals initially filed confidentially on December 31, 2013. Maxim Group LLC is the sole bookrunner on the deal. No pricing terms were disclosed.

 

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Newsletter

Advertisement

You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...

empty

The contract signed between the Israeli government and Pfizer shows clearly and unequivocally that this is a clinical study on humans - The agreement...

Travel

After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.

Advertisement
cialis cialis satış